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ABSTRACT 
Leptin has been implicated as a key upstream mediator of pathways associated with 
coronary vascular dysfunction and disease. The purpose of this investigation was to test the 
hypothesis that leptin modifies the coronary artery proteome and promotes increases in coronary 
smooth muscle contraction and proliferation via influences on Rho kinase signaling. Global 
proteomic assessment of coronary arteries from lean swine cultured with obese concentrations 
of leptin (30 ng/mL) for 3 days revealed significant alterations in the coronary artery proteome (68 
proteins) and identified an association between leptin treatment and calcium signaling/contraction 
(4 proteins) and cellular growth and proliferation (35 proteins). Isometric tension studies 
demonstrated that both acute (30 min) and chronic (3 day, serum-free media) exposure to obese 
concentrations of leptin potentiated depolarization-induced contraction of coronary arteries. 
Inhibition of Rho kinase significantly reduced leptin-mediated increases in coronary artery 
contractions. The effects of leptin on the functional expression of Rho kinase were time-
dependent, as acute treatment increased Rho kinase activity while chronic (3 day) exposure was 
associated with increases in Rho kinase protein abundance.  Proliferation assays following 
chronic leptin administration (8 day, serum-containing media) demonstrated that leptin 
augmented coronary vascular smooth muscle proliferation and increased Rho kinase activity. 
Inhibition of Rho kinase significantly reduced these effects of leptin. Taken together, these 
findings demonstrate that leptin promotes increases in coronary vasoconstriction and smooth 
muscle proliferation and indicate that these phenotypic effects are associated with alterations in 
the coronary artery proteome and dynamic effects on Rho kinase pathway. 
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INTRODUCTION 
Numerous studies have suggested that factors derived from adipose tissue have the 
potential to influence several key mechanisms of obesity-induced coronary disease including the 
promotion of vascular dysfunction and smooth muscle proliferation [22;29;36;44]. For example, 
recent studies support that alterations in the adipokine secretion profile of coronary perivascular 
adipose tissue (PVAT), which surrounds the large conduit arteries of the heart, contribute to 
impaired endothelial-dependent dilation and augmented smooth muscle contraction in the setting 
of obesity [11;26;30;34-36].  Specifically, coronary PVAT has been shown to potentiate coronary 
artery contractions and attenuate vasodilation via effects on Rho kinase signaling and smooth 
muscle CaV1.2 and K+ channels [4;27;34;36].  While these effects are in contrast with the anti-
contractile effects of peripheral PVAT [8;16;51;53], they are consistent with reported increases in 
pro-inflammatory and pro-atherogenic factors in coronary PVAT of subjects with documented 
atherosclerotic disease [9;10;17;22]. However, the specific adipokines and pathways responsible 
for these deleterious influences remain ill defined.  
A growing body of evidence implicates a role for the adipose tissue hormone, leptin, as a 
key upstream mediator of pathways associated with coronary vascular dysfunction and the 
initiation and progression of coronary disease in obesity [2;3]. Plasma concentrations and 
expression of leptin in coronary PVAT are markedly elevated in obese subjects [11;13;15;36;47] 
and leptin receptors (ObR) are highly expressed throughout the wall of diseased coronary arteries 
[6;14;20;36]. Increases in leptin levels (30-90 ng/mL) have been associated with the activation of 
a number of pro-inflammatory pathways (e.g. monocyte chemoattractant protein-1; tumor 
necrosis factor- [7;18]), attenuation of endothelial-dependent dilation, and further impairment of 
obesity-induced endothelial dysfunction [20;21;36]. However, the effects of leptin on coronary 
vascular smooth muscle remain equivocal, as leptin either attenuates or has no effect on 
contractile responses to a variety of agonists in isolated rat aorta [14;38;39].  Importantly, the 
majority of these studies were conducted following acute, short-term exposure to leptin (30-60 
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min). Therefore, understanding of the vascular effects of longer-term leptin exposure is rather 
limited. 
Several studies suggest an interrelationship between leptin signaling and the RhoA/Rho 
kinase pathway, a known regulator of vascular smooth muscle contraction [54-56]. Recent 
findings demonstrate that perivascular overexpression of leptin promotes neointima formation 
after carotid artery injury [44] and that exogenous administration of leptin stimulates proliferation 
of isolated vascular smooth muscle cells from rodents [28;42;45]. Interestingly, activation of the 
RhoA/Rho kinase pathway has been implicated in leptin-mediated increases in vascular smooth 
muscle cell proliferation and hypertrophy [56]. However, contrasting studies have found that leptin 
produces dose-dependent decreases in proliferation [6] and have failed to support a role for 
RhoA/Rho kinase in mediating vascular smooth muscle proliferation [24;48]. Thus, further studies 
are required to identify the effects of short-term and long-term leptin administration on coronary 
vascular smooth muscle contraction and proliferation and to elucidate the precise mechanisms 
involved. 
Accordingly, the purpose of this investigation was to test the hypothesis that leptin 
promotes (1) marked alterations in the coronary proteomic expression profile that favor pathways 
associated with vascular smooth muscle contraction and proliferation; and (2) increases in 
coronary smooth muscle contraction and proliferation via a Rho kinase dependent pathway. 
Findings from this investigation provide novel evidence that leptin contributes to mechanistic 
alterations in coronary vascular function and support the growing paradigm that leptin acts as an 
upstream mediator in the development of obesity-induced coronary disease. 
 
 
MATERIALS AND METHODS 
All experimental procedures and protocols in this investigation were approved by the 
Institutional Animal Care and Use Committee in accordance with the Guide for the Care and Use 
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of Laboratory Animals. Upon sacrifice, hearts from domestic swine (body weight ~50 kg) were 
excised and perfused via aortic cannulation with 4°C, Ca2+-free Krebs buffer (131.5 mM NaCl, 
5mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 25mM NaHCO3, 10 mM glucose). Coronary arteries 
were grossly dissected from the heart, placed under a dissecting scope, and cleaned of 
surrounding myocardium and adventitia. Arteries were then cut into 3 mm rings and subjected to 
the protocols outlined below.  
 
Proteomics 
Coronary arteries were cut into 3 mm rings and were placed in 12-well tissue culture 
dishes with serum-free, low glucose (100 mg/dL) Dulbecco’s Modified Eagle Medium (DMEM: 
Corning Cellgro, Manassas, VA, 10014CM) containing penicillin (100 U/mL) and streptomycin 
(100 μg/mL) (MP Biomedicals, 1670249). Arteries were maintained in a 5% CO2 atmosphere at 
37°C for three days of incubation without (control) or with leptin (30 ng/mL: Sigma Aldrich, St. 
Louis, MO, L4146) for 3 days. Following the culture period, arteries were frozen in liquid N2 and 
delivered on dry ice to the Ohio State University Proteomics Core for protein extraction. Tissues 
were homogenized in 1:10 w/v in ice cold Buffer A (1% digitonin, 0.05% NP-40, NaCl 150 mM, 
Tris 50 mM, pH 7.4) with Complete Protease Inhibitors and PhosSTOP (Roche Diagnostics) using 
a polytron homogenizer (Power Gen 700, Fisher Scientific). Proteins were extracted on ice for 1 
hr, centrifuged at 80,000g for 30 min, and protein concentration of supernatant was determined 
with the Dc Protein Assay (Bio-Rad). Proteins were eluted in Laemmli Reducing Sample Buffer 
for 1D gel electrophoresis. 
 
In-Gel Digestion 
Each band was cut into 8 fractions based on relative protein abundance and placed in 96 
well plates for in-gel digestion. Briefly, gel pieces were washed in 100 µl of 50% methanol/5% 
acetic acid for 30 min.  The wash step was repeated a total of 3 times and slices were left in a 
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storage solution of 50 µl of 50% methanol/5% acetic acid until digestion. Digestion was carried 
out by adding 100 µl 50 mM ammonium bicarbonate (ABC) for 10 min followed by 100 µl 
acetonitrile for 10 min. The gel bands were rehydrated with dithiothreitol (DTT) (prepared as 5 
mg/ml in 50 mM ABC) and incubated for 30 min followed by a 30 min incubation with 
iodoacetamide (prepared as 15 mg/ml iodoacetamide in 50 mM ABC) in the dark. The gel bands 
were washed again with 2 cycles of acetonitrile and 50 mM ABC in 10 and 5 min increments, 
respectively and thendried for 10 min.  The protease was driven into the gel pieces by rehydrating 
them in 50 µL of sequencing grade modified trypsin from Promega (Madison, WI, prepared at 5 
µg/ml with 0.01% ProteaseMAX Surfactant in 50 mM ABC) and incubated at room temperature 
overnight. The peptides were extracted from the polyacrylamide with 50 µl 50% acetonitrile and 
5% formic acid for 10 min a total of 3 times and a final extraction with 50 µl of acetonitrile for 10 
min  and then pooled together. The extracted pools were dried completely and resuspended in 
20 µl of 50 mM acetic acid. 
  
Mass Spectrometry 
The final digests were analyzed using capillary-liquid chromatography-nanospray tandem 
mass spectrometry (Capillary-LC/MS/MS) of global protein. Identification was performed on a 
Thermo Finnigan LTQ orbitrap mass spectrometer equipped with a microspray source (Michrom 
Bioresources Inc, Auburn, CA) operated in positive ion mode.  Samples (6.4 µl from each fraction) 
were separated on a capillary column (0.2X150mm Magic C18AQ 3µ 200A, Michrom 
Bioresources Inc, Auburn, CA) using an UltiMate™ 3000 HPLC system (LC-Packings A Dionex 
Co, Sunnyvale, CA). Each sample was injected into the µ-Precolumn Cartridge (Dionex, 
Sunnyvale, CA) and desalted with 50 mM acetic acid for 5 min. The injector port was then 
switched to injection mode and the peptides were eluted off of the trap onto the column. Mobile 
phase A was 50mM acetic acid in water and acetonitrile was used as mobile phase B. Flow rate 
was set at 2µl/min. Mobile phase B was increased from 2% to 5% in 5 min and again from 5% to 
7 
 
30% in 30 min, then from 30% to 50% in 8 min. The gradient was increased again from 50% to 
85% in 3 min and then kept at 85% for another 1 min before being brought back to 2% in 0.1 min. 
The column was equilibrated at 2% of mobile phase B (or 98% A) for 10 min before the next 
sample injection. MS/MS data was acquired with a spray voltage of 2.2 kV and a capillary 
temperature of 175 °C.  The scan sequence of the mass spectrometer was based on the data 
dependent TopTen™ method in preview mode; the analysis was programmed for a full scan 
recorded between 350-2,000 Da and a MS/MS scan to generate product ion spectra to determine 
amino acid sequence in consecutive scans of the ten most abundant peaks in the spectrum. The 
full scan resolution was set at 30,000 to achieve high mass accuracy MS determination. The CID 
fragmentation energy was set to 35%. Dynamic exclusion is enabled with a repeat count of 1 
within 18 s, a mass list size limit of 500, exclusion duration of 10 s and a low mass width and high 
mass width were set at 30ppm.  
  
Protein Identification and Quantitation 
Sequence information from the MS/MS data was processed by converting the .raw files 
into a mgf files using MsConvert (ProteoWizard) and later merged into a merged file (.mgf) using 
an in-house program, RAW2MZXML_n_MGF_batch (merge.pl, a Perl script) and searched using 
Mascot Daemon by Matrix Science version 2.3.2 (Boston, MA) against the NCBInr Other 
Mammalia Database (version 20150104, 1,412,788 sequences). Trypsin was used as the enzyme 
and four missed cleavages were permitted. Considered variable modifications were oxidation 
(Met), carbamidomethylation (Cys) and deamination (Asn, Gln). The mass accuracy of the 
precursor ions were set to 20ppm and the fragment mass accuracy was set to 0.8 Da. One 13C 
peak was included in the search in case of the accidental pick of 13C peaks. A decoy database 
was also searched to determine the false discovery rate (FDR) and peptides were filtered 
according to the FDR. The significance threshold was set at P < 0.05. Percolator score was used 
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to further validate the search results and the actual FDR was less than 1% after using percolator 
scores. 
Label-free quantitation was performed using the spectral count approach, in which the 
relative protein quantitation is measured by comparing the number of MS/MS spectra identified 
from the same protein in each of the multiple LC/MSMS datasets. Scaffold was used for 
quantitation analysis. The protein filter was set at 99% to ensure the false discovery rate is less 
than 1% and the peptide filter was set at 95%. 
 
Functional Assessment of Isolated Coronary Arteries 
Isometric tension studies on coronary artery rings were performed as previously described 
[27;30]. Briefly, 3 mm coronary artery rings (without PVAT) were mounted in organ baths filled 
with Ca2+-containing Krebs buffer (131.5 mM NaCl, 5mM KCl, 1.2 mM NaH2PO4, 1.2 mM MgCl2, 
25mM NaHCO3, 10 mM glucose, 4mM CaCl2) and maintained at 37°C. Once stabilized at optimal 
passive tension (~4 g), arteries were incubated without (control) or with leptin (30 ng/mL: Sigma 
Aldrich, L4146) and/or fasudil (1 μM: Sigma Aldrich, H139) for 30 minutes (acute exposure) and 
then exposed to increasing concentrations of KCl (10 – 60 mM) and to the thromboxane A2 
receptor agonist, U46619 (1 µM: Tocris, 1932). Coronary arteries cultured in serum-free media 
for 3 days with or without leptin (30 ng/mL: Sigma Aldrich, L4146) and/or fasudil (1 μM: Sigma 
Aldrich, H139) (chronic exposure) were also mounted in organ baths and exposed to increasing 
concentrations of KCl (10 – 60 mM) and to U46619 (1 µM: Tocris, 1932). Acute and chronic 
studies were also conducted in endothelium denuded coronary arteries in which the endothelium 
was removed by gently rubbing fine-tip forceps along the lumen. Active tension development 
(peak tension minus baseline tension) was recorded at each concentration for each group. 
Endothelial denudation was confirmed by <15% relaxation to bradykinin (1 μM: Sigma Aldrich, 
B3259).  
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Western Analysis 
 Following acute (30 minute) or chronic (3 day culture) incubation with or without leptin, 
coronary arteries were frozen in liquid N2 and stored at -80°C. Arteries were homogenized in 70 
µL of Tissue Protein Extraction Reagent (Thermo Scientific, 78510) and total protein was 
quantified as previously described [41]. Equivalent amounts of protein (50 μg) were loaded onto 
10% polyacrylamide gels (Life Technologies, NP0302) for electrophoresis and blotting. 
Membranes were incubated with primary antibody directed against Rho kinase (Rock-2, 1:200, 
Santa Cruz Biotechnology, sc-1851) overnight at 4°C and donkey anti-goat IRDye 800CW 
secondary antibody (1:15,000, Li-Cor, 926-32214) for 1 hour at room temperature. To verify equal 
protein loading, membranes were washed and incubated with antibody to β-actin (1:200, Santa 
Cruz Biotechnology, sc-1616). Immunoreactivity was visualized using a Li-Cor Odyssey CLx 
imaging system. Chameleon Duo (Li-Cor) was used as a protein ladder. Densitometry analyses 
were conducted using Li-Cor Image Studio Lite, version 5.2. Protein levels were normalized to 
levels of β-actin and reported as “% control,” i.e. protein levels from each sample were normalized 
to the average level of the protein in control arteries within the same condition. 
 
Rho Kinase Activity Assay 
 Protein homogenates of the samples outlined above were subjected to a commercially 
available enzyme immunoassay for the detection of active Rho kinase (Rho-associated Kinase 
(ROCK) Activity Assay, Millipore, CSA001). Briefly, equal amounts of protein (50 µg) from each 
sample were added to plates pre-coated with recombinant MYPT1. A detection antibody specific 
for phosphorylated MYPT1 and a HRP-conjugated secondary antibody were added, respectively. 
The amount of phosphorylated substrate was measured by adding the chromogenic substrate 
tetramethylbenzidine and reading the absorbance signal at 450 nm. Absorbance values were then 
normalized to a standard curve of active recombinant ROCK-II enzyme.  
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Proliferation Assays 
Additional culture studies were conducted in which arteries were incubated in serum-
containing (30% fetal bovine serum, Glibco, 10437-028), low glucose (100 mg/dL) Dulbecco’s 
Modified Eagle Medium (DMEM: Corning Cellgro, 10014CM) containing penicillin (100 U/mL) and 
streptomycin (100 μg/mL) (MP Biomedicals, 1670249) at 37°C in a 5% CO2 atmosphere. Arteries 
were incubated with or without leptin (30 ng/mL: Sigma Aldrich, L4146) and/or fasudil (1 μM: 
Sigma Aldrich, H139) for 8 days, with media changes conducted every 2 days. To confirm 
functional responses at this time point, both intact and denuded arteries were subjected to the 
isometric tension studies outlined above. In a subset of untreated and leptin treated arteries, 5-
Bromo-2’-deoxyuridine (BrdU; 20 μmol/L) was added to the culture medium for the final 6 hours 
of culture. Arteries were then fixed in 10% formalin, paraffin embedded, and processed for BrdU 
labeling in nuclei utilizing an immunohistochemical detection assay (BrdU Labeling and Detection 
Kit II, Roche, 11299964001). Positive staining for BrdU-labeled nuclei indicates DNA synthesis, 
a marker of cellular proliferation. To specifically investigate vascular smooth muscle proliferation, 
arteries from all treatment groups were formalin fixed, paraffin embedded, and processed for co-
immunostaining with anti-α smooth muscle actin (1:50, Abcam, ab5694) and anti-proliferating cell 
nuclear antigen (PCNA, 1:2,000, Abcam, ab29). Mach 2 Double Stain 2 (Biocare Medical, 
MRCT525) was used as secondary with chromogens Vulcan Fast Red and 3,3′-
Diaminobenzidine, respectively. Immunohistochemistry was performed in conjunction with the 
Indiana University Health Pathology Laboratory (Indianapolis, IN). Slides were imaged at 20X 
magnification. Four distinct fields of view were captured per artery and data were averaged for 
n=1. Quantitation of positive staining was performed using the open source modification of Image 
J (Fiji) [43] and a custom modification of the trichrome quantification macro (The University of 
Chicago Integrated Light Microscopy Core Facility). Positive PCNA staining was quantitated in 
artery regions also staining positively for α-smooth muscle actin. Data are reported as “% control,” 
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i.e. percent positive staining from each sample was normalized to the average level of positive 
staining in untreated, control arteries.  
 
Statistical Analyses 
 Statistical comparisons of proteomic results were performed on proteins which met 
Scaffold false discovery rate (FDR) criterion by Student’s t-test. Proteins with P < 0.05 were 
considered significantly different between treatment groups. Protein lists and corresponding 
expression values were uploaded onto the Ingenuity Pathway Analysis software server (content 
version: 24718999) and analyzed to interpret cellular functions and canonical pathways 
associated with alterations in the proteomic profile between treatment groups. For isometric 
tension studies, a two-way ANOVA was used to test the effects of leptin and/or inhibitors (Factor 
A) relative to concentrations of specific agonists (Factor B). When statistical differences were 
found with ANOVA (P < 0.05), a Student-Newman-Keuls multiple comparison test was performed. 
A Student’s t-test was used to compare the results of Western blot, Rho Kinase activity, and 
proliferation assays. Data are presented as mean ± SE with “n” equal to number of pigs studied. 
SigmaPlot version 11.0 (Systat Software Inc, San Jose, CA) was used for all statistical analyses 
and generation of figures.  
 
RESULTS 
Effect of leptin exposure on the coronary proteomic expression profile  
To investigate potential factors and pathways affected by leptin exposure, global 
proteomic profiling was performed on coronary arteries cultured in the presence or absence of 
leptin (30 ng/mL) for 3 days. This non-biased target discovery approach detected significant 
alterations in 69 proteins (P ≤ 0.05) in leptin treated arteries. A complete list of the 793 detected 
proteins is provided in Online Resource 1. The top 15 unique upregulated and downregulated 
proteins are listed in Table 1. Ingenuity Pathway Analysis (IPA) software identified significant 
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associations (P<0.001) between leptin treatment and numerous cellular functions, namely 
calcium signaling (4 proteins) and cellular growth and proliferation (35 proteins). These findings 
are of interest, as previous studies have suggested a potential link between leptin and vascular 
reactivity [14;20;36;38] and proliferation [28;44]. Additional cellular pathways/processes identified 
include cellular movement, migration, and invasion (25 proteins), cell spreading (6 proteins) and 
quantity of smooth muscle cells (4 proteins).  
 
Acute and chronic leptin administration augments coronary artery contractions 
The effects of leptin on coronary vascular reactivity were examined by comparing KCl-
induced contractions of coronary arteries following short-term, acute (30 min) and long-term, 
chronic (3 day, serum-free culture) exposure to “obese” concentrations of leptin (30 ng/mL), i.e., 
plasma concentrations typically reported in obese subjects [33;46]. Overall contractile responses 
of acute leptin treated arteries were significantly augmented (P = 0.04), with maximal tension 
development increased by 1.5 ± 0.2 g at 60 mM KCl (Figure 1A). Chronic exposure to leptin also 
augmented overall active tension development to KCl (P<0.001), with an increase of 2.7 ± 0.49 g 
at 60 mM (Figure 1B). Control responses to KCl were reduced following 3 days of culture (P = 
0.006, Figure 1B vs 1A). This reduction in contraction was also observed in response to the 
thromboxane A2 receptor agonist, U46619 (1 µM, P = 0.04), although leptin had no effect on 
U46619 contractions following acute (P = 0.58) or chronic (P = 0.34) exposure (Online Resource 
2, Figure I).  KCl contractions in control and leptin treated arteries were unaffected by removal of 
the endothelium, and similar effects of leptin were observed in endothelium denuded arteries 
(confirmed by <30% relaxation to 1µM bradykinin) following both acute (Online Resource 2, 
Figure IIA) and chronic (Online Resource 2, Figure IID) exposure.  
 
 
 
13 
 
Role of Rho kinase in leptin-mediated coronary contraction 
 To investigate the role of Rho kinase signaling in mediating the functional effects of leptin, 
coronary arteries were co-incubated with/without leptin (30 ng/mL) and/or the Rho kinase inhibitor, 
fasudil (1 µM). Acute fasudil treatment significantly reduced vasoconstriction to KCl (10 – 60 mM) 
compared to untreated (control) arteries (P < 0.001, Figure 2A). In contrast, fasudil treatment had 
no effect on contractile responses to KCl (10 – 60 mM) in untreated (control) arteries cultured for 
3 days (P = 0.50, Figure 2B). Fasudil administration significantly decreased the effect of acute 
(P < 0.001, Figure 2C) and chronic (P = 0.01, Figure 2D) leptin exposure on KCl-induced 
contractions. However, this effect of fasudil was markedly greater following acute (~3.8 g at 
concentrations >40 mM) versus chronic exposure (~1.4 g at concentrations >40 mM) to leptin (P 
< 0.001). KCl contractions in arteries treated with leptin and/or fasudil were unaffected by removal 
of the endothelium, and similar effects of fasudil were observed in endothelium denuded arteries 
following both acute (Online Resource 2, Figure IIB and IIC) and chronic (Online Resource 2, 
Figure IIE and IIF) exposure. 
 
Effects of leptin on Rho kinase expression and activity 
 Further analyses were conducted to examine the effects of leptin on Rho kinase 
abundance and activity. Western blot analyses revealed no difference in normalized protein 
abundance of Rho kinase in acute leptin treated arteries (P = 0.61, Figure 3A and 3B). A 
commercially available Rho-associated kinase (ROCK) activity assay demonstrated that acute 
leptin exposure significantly increased the level of Rho kinase activity from 0.50 ± 0.07 µU/µL in 
untreated arteries to 1.61 ± 0.25 µU/µL in leptin treated arteries (P = 0.01, Figure 3C). Following 
chronic exposure to leptin (3 day, serum-free culture), the abundance of Rock-2 protein was 
increased ~3.5-fold relative to untreated cultured arteries (P = 0.009, Figure 3D and 3E). While 
Rho kinase activity level was increased relative to acute untreated arteries following 3 days of 
culture, chronic exposure to leptin did not affect overall Rho kinase activity, relative to untreated 
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time-control (1.73 ± 0.36 µU/µL in untreated versus 1.60 ± 0.16 µU/µL in leptin treated arteries; P 
= 0.92, Figure 3F).  
 
Leptin and vascular smooth muscle cell proliferation 
 Additional studies were conducted to directly investigate the effects of leptin on coronary 
vascular proliferation. In initial experiments, coronary arteries were cultured in serum-containing 
media for 8 days in the presence or absence of leptin, with 5-Bromo-2’-deoxyuridine (BrdU) added 
to the media for the final six hours of culture. Systematic quantitation of the BrdU staining pattern 
using ImageJ revealed a ~32% increase in BrdU-positive nuclei in leptin treated relative to 
untreated, control arteries (P = 0.02, Online Resource 2, Figure III). Based on these findings, 
further studies were conducted in arteries cultured with or without leptin (30 ng/mL) and/or fasudil 
(1 µM) for 8 days. The functional effects of leptin and/or fasudil were conserved in both 
endothelium intact (Online Resource 2, Figure IVA-C) and endothelium denuded arteries 
(Online Resource 2, Figure IVA-C) at this time point. Overall KCl-induced vasoconstriction in 
untreated, control arteries was reduced following 8 days of culture (P < 0.001, Online Resource 
2, Figure IVA versus 1B). This reduction in contraction was also observed in response to U46619 
(1 µM, P = 0.002), although leptin had no effect on U46619 contractions following chronic, 8 day 
exposure (P = 0.61, Online Resource 2, Figure I). 
To investigate the role of Rho kinase on leptin-mediated increases in vascular smooth 
muscle proliferation, arteries were co-immunostained for α-smooth muscle actin and proliferating 
cell nuclear antigen (PCNA). Systematic quantitation of the PCNA staining pattern within the 
vascular smooth muscle layer revealed a ~22% increase in PCNA-positive nuclei in leptin treated 
(Figure 4B) relative to untreated, control arteries (P = 0.04, Figure 4A). Treatment with fasudil 
alone had no effect on proliferation relative to untreated control arteries (P = 0.50). Co-treatment 
with leptin and fasudil (Figure 4C) significantly reduced the effect of leptin on vascular smooth 
muscle proliferation (P = 0.002, Figure 4D). Increases in proliferation with leptin treatment (8 day, 
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serum-containing culture) were associated with a modest increase in Rho kinase protein 
abundance  (P = 0.18, Figure 5A and 5B) and a significant increase in Rho kinase activity, 
averaging 1.52 ± µU/µL in untreated and 2.40 ± 0.12 µU/µL in leptin treated arteries (P = 0.03, 
Figure 5C). The effect of leptin on Rho kinase activity was significantly reduced by co-incubation 
with fasudil (P = 0.002, Figure 5C). 
 
DISCUSSION 
 The purpose of this investigation was to test the hypothesis that leptin modifies the 
coronary proteomic expression profile and promotes increases in coronary smooth muscle 
contraction and proliferation via influences on Rho kinase signaling.  The major new findings are: 
(1) chronic exposure to obese concentrations of leptin (30 ng/mL, 3 day culture) induces marked 
alterations in the coronary artery proteome (68 proteins) with a significant influence on calcium 
signaling/contraction and cellular growth and proliferation; (2) acute (30 min) and chronic (3 day, 
serum-free media) exposure to leptin potentiates voltage-dependent contraction of isolated 
coronary arteries; (3) acute and chronic leptin-mediated increases in coronary vasoconstriction 
occur concomitantly with increases in activity and protein abundance of Rho kinase, respectively; 
(4) chronic leptin administration (8 day, serum-containing media) augments vascular smooth 
muscle proliferation via increases in Rho kinase activity; and (5) the contractile and proliferative 
effects of leptin exposure were abolished by the Rho kinase inhibitor fasudil. Taken together, 
these findings provide novel evidence in support of the paradigm of leptin as an upstream 
mediator that contributes to marked phenotypic alterations in coronary smooth muscle in the 
setting of obesity.   
 
Leptin as an upstream mediator of coronary vascular disease 
            Although recent findings have implicated leptin as an upstream paracrine mediator of a 
key network of pathways associated with obesity-induced coronary vascular disease, no study 
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has systematically investigated the potential factors and/or pathways involved. Accordingly, we 
conducted a global proteomic assessment of coronary arteries with and without chronic (3 day) 
exposure to “obese” concentrations of leptin, i.e., plasma concentrations typically reported in 
obese subjects (30 ng/ml) [33;46]. This non-biased discovery approach revealed that leptin 
administration markedly influences the abundance of numerous proteins (Table 1). These data 
support that leptin signaling alters the expression of a large number of factors which have the 
potential to mediate additional paracrine effects within the vascular wall. Indeed, Ingenuity 
Pathway Analysis (IPA) identified alterations within several key cellular processes in leptin treated 
arteries. Specifically, IPA revealed that the detected changes in the proteomic expression profile 
corresponded to pathways associated with calcium signaling (e.g., calreticulin, cAMP-dependent 
protein kinase type II, tropomyosin) and cellular growth and proliferation (e.g., myotrophin, 
myoferlin, fibrillin-1). These findings are consistent with a previous proteomics assessment from 
our laboratory which documented an altered secretion profile of coronary PVAT in obese swine 
which corresponded with pathways associated with cellular growth and proliferation and cellular 
movement [30]. Furthermore, these alterations in the secretion profile were also associated with 
increases in vascular smooth muscle contraction [30]. Together with reports of elevated 
expression of leptin in obese coronary PVAT [36], the current proteomic findings support a role 
for leptin in coronary vascular contraction and proliferation in the setting of obesity. 
These findings have significant (patho)physiologic implications. Recent studies from our 
laboratory and others indicate that obesity augments coronary smooth muscle CaV1.2 current and 
voltage dependent increases in intracellular Ca2+ concentration [4;23;30]. Changes in intracellular 
Ca2+ handling are known to influence both contraction and phenotypic modulation of coronary 
smooth muscle (i.e. development of a proliferative and/or osteogenic phenotype) [31;50;52]. 
Recent data also indicate that leptin increases proliferation of isolated smooth muscle cells [19;28] 
and that perivascular leptin overexpression promotes neointimal formation in peripheral (non-
coronary) arteries [44]. Taken together, the present findings and those of others support the 
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growing paradigm regarding a mechanistic role for heightened levels of leptin in obesity-induced 
coronary disease. 
 
Leptin and coronary smooth muscle contraction 
Current understanding of the effects of leptin on vasoconstriction is rather limited and 
conflicting. Acute leptin administration has been shown to inhibit angiotensin (Ang) II-induced 
contractions of isolated rat aorta by diminishing the increase in cytosolic [Ca2+] in smooth muscle 
cells [14]. In contrast, other studies fail to demonstrate an effect of leptin on contractile responses 
to Ang II, noradrenaline, or endothelin-1 [14]. Chronic systemic leptin administration in normal 
rats has been shown to produce modest increases in phenlyephrine-induced contractions of aortic 
rings [32]. These disparate findings are likely related to differences in the concentration of leptin 
used (0.01 – 100 nmol/L), duration of treatment, vascular bed being studied, and/or the overall 
health status of the animal model. Results from this study demonstrate that “obese” 
concentrations of leptin (30 ng/mL) potentiate depolarization-induced contraction of coronary 
arteries following acute (30 min, Figure 1A) and chronic administration (3 day culture, Figure 
1B). These distinct coronary vascular effects of leptin are consistent with recent studies 
documenting a unique contractile effect of coronary PVAT on vascular smooth muscle compared 
to other artery/adipose tissue depots that is further augmented in the setting of obesity [30]. 
Results also demonstrate that leptin has little to no effect on thromboxane A2 receptor-mediated 
contractions (Online Resource 2, Figure II), suggesting that the functional effects of leptin 
observed in this study are specifically related to depolarization-induced contraction. This effect of 
leptin is consistent with reports of augmented coronary vasoconstriction in the setting of obesity 
[5] and, together with both elevated plasma leptin concentration [15;46] and increased local 
(coronary PVAT) leptin production [11;36] in the setting of obesity, support the potential for leptin 
(plasma and/or local PVAT-derived) to contribute to the development of coronary vascular smooth 
muscle dysfunction. 
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Rho kinase and coronary smooth muscle contraction  
The mechanisms by which leptin influences coronary vascular smooth muscle function 
remain ill defined. Recent studies suggest a connection between leptin and RhoA/Rho kinase 
signaling [54-56], which is a well-known major regulator of smooth muscle contraction and 
vascular tone [25]. However, whether RhoA/Rho kinase contributes to the coronary vascular 
effects of leptin has not been determined. Data from this investigation support a role for Rho 
kinase in leptin-mediated increases in depolarization-induced coronary artery contraction. These 
findings are consistent with previous studies from our laboratory which found marked increases 
in RhoA expression in obese coronary PVAT and that inhibition of Rho kinase attenuates PVAT-
mediated increases in coronary vascular smooth muscle contraction [30]. We propose the effects 
of leptin occur independent of influences on coronary endothelium as studies in endothelium 
denuded arteries (Online Resource 2, Figure II) were directionally consistent with studies in 
endothelium intact arteries. 
The present findings also indicate that the effects of leptin on the Rho kinase pathway are 
time-dependent. Acutely, inhibition of Rho kinase significantly inhibits coronary artery contractions 
both in the presence (Figure 2C) and absence (Figure 2A) of leptin, whereas following chronic 
culture for 3 days, the inhibition of Rho kinase significantly inhibits coronary artery contractions 
only in the presence of leptin (Figure 2D). It is important to note that, in the absence of leptin, the 
contribution of Rho kinase to KCl-induced contractions was reduced following organ culture 
(Figure 2B versus 2A) and that the effects of the Rho kinase inhibitor, fasudil, on contractile 
responses following chronic (Figure 2D) compared to acute (Figure 2C) leptin exposure were 
relatively modest. Interestingly, these findings are consistent with previous reports of a reduced 
contribution of Rho kinase to maximal KCl contractions in obese compared to lean arteries [30]. 
The time-dependent effects of leptin on Rho kinase are further highlighted data indicating 
that acute (30 min) leptin treatment increased Rho kinase activity (Figure 3C), independent of 
changes in Rho kinase expression (Figure 3A and 3B), while chronic exposure to leptin (3 day 
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culture) was associated with increased Rho kinase protein abundance (Figure 3D and 3E) with 
little/no change in overall Rho kinase activity (Figure 3F). It should be noted, however, that overall 
Rho kinase activity of cultured arteries was significantly elevated relative to untreated, acute 
controls (Figure 3F versus Figure 3C). Altogether, these findings indicate that the coronary 
vascular actions of leptin are mediated, at least in part, via time-dependent influences on Rho 
kinase activity (acute) and expression (chronic) and are consistent with phenotypic changes 
observed in coronary artery disease. 
Although the proteomic analyses in this study indicated alterations in pathways involved 
in the regulation of vascular tone, no significant alterations in proteins involved in the regulation 
of Rho kinase activation (e.g., RhoA, rho GDP-dissociation inhibitor, rho GTPase activating 
protein) or in Rho kinase substrates involved in contraction (e.g., MYPT-1, CPI-17, myosin light 
chain MLC) were detected by Ingenuity Pathway Analysis following chronic, 3 day leptin treatment 
(Online Resource 1). However, it is important to consider that a proteomics approach excludes 
the examination of the phosphorylation status of key regulatory proteins in this cascade as well 
as the examination of potential lipid mediators. Despite the detection of a direct connection, the 
proteomic analyses provide valuable insights into the complex cellular processes and pathways 
influenced by chronic leptin exposure.  
 
Leptin and coronary vascular smooth muscle proliferation 
Based on the current and prior evidence supporting that leptin is associated with cellular 
growth and proliferation pathways, additional experiments were performed to directly investigate 
the effects of leptin on coronary proliferation. In these studies, coronary arteries were cultured in 
serum-containing media for 8 days. Quantitation of co-immunostaining for PCNA and α-smooth 
muscle actin revealed a significant increase in PCNA-positive vascular smooth muscle cells in 
arteries exposed to leptin (30 ng/ml) that was inhibited by co-incubation with fasudil (Figure 4). 
The leptin-induced increase in coronary proliferation reported in this study was associated with a 
20 
 
modest increase in Rho kinase protein abundance (Figure 5A and 5B) and a significant increase 
in Rho kinase activity (Figure 5C) relative to untreated, controls. These data further support that 
the effects of leptin on Rho kinase protein abundance and activity are dependent, at least in part, 
on the time-course of administration (e.g., acute, 3 day, 8 day) and culture condition (e.g., serum-
free versus serum-containing). Although the precise molecular mechanisms responsible for this 
dynamic effect of leptin on Rho kinase signaling are presently unknown, we postulate that these 
effects occur independently of influences on coronary endothelium, as endothelial denudation 
had little to no effect on functional responses following chronic, 8 day treatment with leptin and/or 
fasudil (Online Resource 2, Figure IV). However, the possibility that the observed effects of 
leptin on proliferation are mediated by factors released from endothelial cells cannot be ruled out. 
Our findings are consistent with other studies which have documented leptin-induced vascular 
smooth muscle hypertrophy [49;56], smooth muscle proliferation [19;28;44], and neointimal 
formation [42;44] in rodent models, although contrasting evidence in rat aortic smooth muscle 
cells exposed to Ang II [40] and in a human smooth muscle cell line [6] have also been reported. 
However, to our knowledge, the present data are the first to demonstrate that patho-
physiologically relevant (“obese”) concentrations of leptin are capable of promoting vascular 
smooth muscle proliferation and to provide evidence in support of a mechanistic linkage between 
Rho kinase and leptin-mediated increases in proliferation in the coronary circulation.  
 
Limitations 
 Although this investigation utilizes arteries from the translationally relevant porcine 
coronary circulation, relevant obese concentrations of leptin, and a time course (i.e., acute and 
chronic) of leptin administration, it is presently unclear to what extent these findings translate to 
the human condition. However, the present study is among the first to systematically investigate 
the factors and pathways involved in leptin-induced phenotypic alterations of coronary arteries 
(i.e., increased contraction and proliferation). While functional data support that the vascular 
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smooth muscle layer is responsible for the observed effects of leptin, the precise factors and cell 
types involved remain to be definitively determined. Additionally, a pharmacologic approach was 
utilized to interrogate the Rho kinase pathway in this study. Based on reported IC50 values for 
fasudil [1;12;37], a concentration of 1 µM was chosen to potently inhibit Rho kinase and minimize 
off target effects. Although the possibility of non-specific effects cannot be ruled out, data in which 
fasudil diminishes Rho kinase activity in this study (Figure 5C) support the specificity and efficacy 
of this pharmacologic approach. However, future genetic knockdown (e.g. antisense 
oligonucleotides) studies to confirm the present findings are warranted.  
 
Conclusions & Implications 
 The present data provide novel evidence that relevant obese concentrations of leptin 
promote increases in coronary vasoconstriction and smooth muscle proliferation and that these 
phenotypic effects are directly associated with alterations in the coronary artery proteome and 
dynamic effects on the Rho kinase pathway. Although the current studies were conducted using 
(patho)physiologically relevant (“obese”) concentrations of leptin, a critical question remains as to 
the extent to which locally produced versus circulating leptin contributes to the initiation and 
progression of coronary disease in vivo. Future studies to directly investigate the mechanisms 
responsible for the time-dependent effects of leptin on Rho kinase protein abundance and activity 
are also warranted. Regardless, this investigation provides novel evidence in support of leptin as 
an upstream mediator of the hypercontractile and proliferative coronary smooth muscle 
phenotype reported in obesity-induced coronary disease.  
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Table 1. Protein Expression Profile of Leptin-treated Coronary Arteries 
Gene Name Protein Name Fold         Change P Value IPA 
Upregulated Proteins 
MYOZ2 Calsarcin-1 (myozenin-2) 5.8 0.02 4 
RAB21 Ras-related protein, Rab-21 4.8 0.0002  
SORBS1 Sorbin and SH3 domain-containing protein 1, isoform 1 4.4 0.007 5 
LASP1 LIM and SH3 domain protein 1 3.2 0.05 2,3 
EIF6 Eukaryotic translation inititation factor 6, isoform X1 1.6 0.05 2 
ADIRF* Adipogenesis regulatory factor 1.5 0.02  
Cald1 Non-muscle caldesmon, isoform X1 1.5 0.005  
MTPN Myotrophin 1.5 0.03 2 
S100A11 Protein S100-A11 1.4 0.04 2,3 
RPL12 60S ribosomal protein L12 1.3 0.01  
TPM4 Tropomyosin alpha-4 chain, isoform X3 1.3 0.02 1 
TPM4 Tropomyosin alpha-4 chain, isoform X2 1.3 0.03 1 
TPM4 Tropomyosin alpha-4 chain, isoform X1 1.3 0.02 1 
TUBA1C Tubulin alpha chain-like 1.2 0.02 2,3 
TPM2 Tropomyosin beta chain, isoform X1 1.2 0.03 1 
Downregulated Proteins 
MYOF Myoferlin 7.6 0.03 2,4 
ALDH4A1 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial 6.1 0.009  
ATPIF1 ATPase inhibitor, mitochondrial precursor 4.9 0.00003 2 
SRI Sorcin 4.8 0.00003  
SSR4 Translocon-associated protein subunit delta, isoform X1 2.6 0.04  
PRKAR2A cAMP-dependent protein kinase type II-alpha regulatory subunit 2.6 0.04 1,2,3 
CSPG4 Chondroitin sulfate proteoglycan 4 2.4 0.03 2,3,5 
HSP90AA1 Heat shock protein HSP 90-alpha 2.3 0.02 2,3 
SLC25A3 Phosphate carrier protein, mitochondrial 2.3 0.02  
FBN1 Fibrillin-1 2.2 0.02 2,3,5 
PDIA4 Protein disulfide-isomerase A4 precursor 2.1 0.04  
RNH1 Ribonuclease inhibitor 2.1 0.03 2,3 
RPN2 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 2 precursor 2.0 0.02  
GLUD1 Glutamate dehydrogenase 1, mitochondrial precursor  1.8 0.0004  
IGTA1* Integrin alpha 1 1.8 0.04   
Values for fold change in expression of coronary arteries cultured for three days with leptin (30 ng/mL)  versus untreated controls 
(n=4 each group). Ingenuity Pathway Analysis (IPA): 1Calcium signaling, 2Cell proliferation, 3Cell movement, migration, invasion, 
4Quantity of smooth muscle cells, 5Cell spreading. *Bos taurus homolog.  
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Fig. 1 Leptin augments depolarization-induced coronary artery contractions. Acute (30 min) 
exposure to leptin (30 ng/mL) increased KCl-induced contractions ~1.3 g at doses >40 mM (n=9 
[A]). Chronic (3 day culture in serum-free media) leptin administration (30 ng/mL) increased 
tension development ~2.5 g at doses >40 mM (n=4 [B]) 
 
Fig. 2 Role of Rho kinase in leptin-mediated coronary contraction. In the absence of leptin, acute 
(n=9 [A]), but not chronic (n=4 [B]) treatment with the Rho kinase inhibitor, fasudil (1 µM), 
diminished vasoconstriction to KCl. Inhibition of Rho kinase reduced the effect of both acute (n=9 
[C]) and chronic (n=4 [D]) leptin administration on KCl-induced contractions. However, the fasudil-
mediated reduction in tension was greater following acute (C) versus chronic (D) leptin exposure 
 
Fig. 3 Effects of acute versus chronic leptin treatment on Rho kinase. Representative blots of Rho 
kinase protein abundance in coronary arteries following acute (A) and chronic (3 day culture in 
serum free media) (D) leptin exposure. Average data are expressed as % relative to control. Acute 
leptin treatment increased Rho kinase activity (C) in the absence of a change in protein 
abundance (B). Following chronic exposure, protein abundance was significantly elevated in 
leptin treated arteries (E), while no difference in overall Rho kinase activity was detected relative 
to untreated control arteries (F). All groups n = 3. *P<0.05, leptin versus control. †P<0.05, versus 
acute control 
 
Fig. 4 Leptin augments coronary vascular smooth muscle proliferation via effects on Rho kinase. 
Representative images of α-smooth muscle actin (red) and proliferating cell nuclear antigen 
(brown) co-immunostaining of untreated, control (A), leptin treated (B), and leptin and fasudil co-
treated arteries (C) following chronic, 8 day culture in serum-containing media. The increase in 
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PCNA-positive nuclei in leptin treated, relative to untreated arteries was significantly reduced by 
inhibition of Rho kinase with fasudil (D). All groups n = 5. *P<0.05, leptin versus control. **P<0.05 
leptin versus leptin+fasudil 
 
Fig. 5 Effects of leptin-induced vascular smooth muscle proliferation on Rho kinase. 
Representative blot of Rho kinase protein abundance in control versus leptin treated arteries 
following 8 days of culture in serum-containing media [A]. Leptin administration significantly 
increased Rho kinase activity (C), while only a modest increase in Rho kinase protein abundance 
was detected (B). The effect of leptin on Rho kinase activity was abolished by co-incubation with 
fasudil (C) All groups n=5. *P<0.05, leptin versus control. **P<0.05 leptin versus leptin+fasudil 
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